Biotest Aktiengesellschaft (BIO.DE)

XETRA - XETRA Delayed Price. Currency in EUR

41.40

-0.20

(-0.48%)

At close: 05:36PM CET

Loading interactive chart...

GuruFocus.com
Biotest AG (WBO:BIO3) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Biotest AG reports a 35% revenue increase and FDA approval for Yimmugo, setting the stage for U.S. market entry in 2025.
Pharmaceutical Technology
Biotest wins FDA approval for plasma protein therapy
The US Food and Drug Administration (FDA) approved Biotest’s Yimmugo for the treatment of primary antibody deficiencies.